ABT Stock: Barclays Reaffirms Buy on Abbott Laboratories Near 52-Week Low
By TrendSpider Editor
Barclays analyst Matt Miksic has confirmed a Buy rating on Abbott Laboratories with a revised price target of $143, down slightly from a prior target of $144, even as shares trade near their 52-week low. Abbott currently sits at $96.41, representing a decline of 0.43% on the session, and is trading
ABT Stock: Barclays Reaffirms Buy on Abbott Laboratories Near 52-Week Low
Barclays analyst Matt Miksic has confirmed a Buy rating on Abbott Laboratories with a revised price target of $143, down slightly from a prior target of $144, even as shares trade near their 52-week low. Abbott currently sits at $96.41, representing a decline of 0.43% on the session, and is trading much closer to its 52-week low of $93.92 than its 52-week high of $139.05. The reaffirmed bullish stance from Barclays highlights a significant gap between where the stock trades today and where at least one major Wall Street firm believes it belongs.
Key Drivers of the ABT Stock Move
- Main Catalyst: Barclays analyst Matt Miksic confirmed a Buy rating on Abbott Laboratories while trimming the price target modestly to $143 from $144, signaling continued confidence in the name despite a slight reduction in the upside estimate.
- Bull Case: At a current price of $96.41, the Barclays price target of $143 implies substantial upside from current levels. The consensus average price target also sits at $143, suggesting the broader analyst community is aligned with a meaningfully higher valuation for ABT.
- Bear Case: The minor price target cut from $144 to $143, while small, suggests even a bullish analyst is making modest downward revisions. More concerning is where the stock sits today, trading just $2.49 above its 52-week low of $93.92, indicating persistent selling pressure that a reiterated Buy rating has so far failed to reverse.
The forward setup for Abbott is a study in contrasts. The stock is pinned near its lowest levels in the past year despite carrying a Buy rating and a consensus price target of $143 from the analyst community. That kind of divergence between Wall Street sentiment and price action often reflects broader macro pressure, sector rotation, or company-specific uncertainty that has yet to be resolved. Abbott is a diversified healthcare giant with exposure to medical devices, diagnostics, nutrition, and pharmaceuticals, meaning it can be sensitive to shifts in hospital spending, consumer health trends, and regulatory developments. The fact that a high-profile analyst is trimming, even marginally, while reaffirming a positive view could indicate that near-term estimates are under some pressure even if the long-term thesis remains intact. Investors will be watching closely for any upcoming earnings updates or guidance revisions that could serve as a catalyst to either close the gap to analyst targets or push the stock further toward its 52-week floor.
ABT Analyst Ratings and Price Targets
- Barclays (Matt Miksic): Confirmed Buy rating | Price target revised to $143 from a prior target of $144
The consensus rating on Abbott Laboratories carries an average price target of $143, aligning exactly with the Barclays target. With ABT trading at $96.41 as of today, April 20, 2026, the average price target represents a significant premium to the current market price. There were no upgrades or downgrades associated with this action, as the rating was a confirmation of an existing Buy stance.
ABT Seasonality
The spring period heading into late April and early May has historically been an active window for healthcare sector earnings, and Abbott's positioning near a 52-week low into this period could set up a meaningful directional move depending on how upcoming quarterly results are received. Historically, large-cap healthcare names with strong dividend profiles like Abbott have tended to attract value-oriented buyers when trading near multi-month lows ahead of earnings season.
ABT Relative Performance
Abbott's current price of $96.41 places it down 30.6% from its 52-week high of $139.05, underperforming the broader large-cap healthcare space by a wide margin over the trailing year. Trading just $2.49 above its 52-week low of $93.92, ABT is among the weaker performers in its peer group on a trailing basis, a notable position for a company that commands a consensus analyst price target of $143 and carries a Buy rating from Barclays.